Teligent Inc. (NASDAQ:TLGT) and Soligenix Inc. (NASDAQ:SNGX) compete with each other in the Biotechnology sector. We will analyze and contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teligent Inc.	65.86M	0.83	36.26M	-0.38	0.00
Soligenix Inc.	5.24M	2.98	8.90M	-0.83	0.00

Demonstrates Teligent Inc. and Soligenix Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 provides us the return on equity, net margins and return on assets of both businesses.

	Net Margins	Return on Equity	Return on Assets
Teligent Inc.	-55.06%	-70.2%	-15%
Soligenix Inc.	-169.85%	-142.4%	-87%

Risk & Volatility

Teligent Inc. has a 1.59 beta, while its volatility is 59.00% which is more volatile than Standard & Poor’s 500. Soligenix Inc.’s 31.00% more volatile than Standard & Poor’s 500 which is a result of the 1.31 beta.

Liquidity

Teligent Inc.’s Current Ratio is 1.3 while its Quick Ratio is 0.9. On the competitive side is, Soligenix Inc. which has a 3.3 Current Ratio and a 3.3 Quick Ratio. Soligenix Inc. is better positioned to pay off short and long-term obligations compared to Teligent Inc.

Institutional & Insider Ownership

The shares of both Teligent Inc. and Soligenix Inc. are owned by institutional investors at 83.4% and 23.1% respectively. Teligent Inc.’s share held by insiders are 0.3%. Comparatively, 14.4% are Soligenix Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Teligent Inc.	0%	-9.41%	-26.67%	-61.01%	-43.17%	12.41%
Soligenix Inc.	2.2%	3.34%	-17.7%	-40%	-54.41%	8.14%

For the past year Teligent Inc. was more bullish than Soligenix Inc.

Summary

Teligent Inc. beats on 7 of the 10 factors Soligenix Inc.

Teligent, Inc., a specialty generic pharmaceutical company, develops, formulates, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The companyÂ’s products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract formulation and contract manufacturing services comprising formulating, testing, and/or manufacturing prescription drugs and medical devices. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric CrohnÂ’s disease and acute radiation enteritis. This segment also offers SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase IB clinical trial for the treatment of vaccine against ricin toxin poisoning; VeloThrax, an anthrax vaccine candidate; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of melioidosis. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.